ClinicalTrials.gg
RecruitingNCT07698600Updated Oct 14, 2026

A Clinical Trial to Look at the Safety and Immune Responses of the RNA-based Vaccine BNT168 in Adults Living With or Without HIV

A Phase 1 interventional study of BNT168 and Placebo in HIV -1 Infection, sponsored by BioNTech SE. Recruiting at 4 sites in 2 countries. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-14.

Primary conditionAcquired Immunodeficiency Syndrome(the registry's first term)UnverifiedIs this wrong?The registry often attaches Acquired Immunodeficiency Syndrome to studies about something else, and this study's title and listed conditions do not name it. No better condition is named, so the registry's term is kept.

Sponsored by BioNTech SE · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Oct 14, 2026First site in South Africa3 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
126
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

This study will test a new ribonucleic acid (RNA)-based vaccine called BNT168 in adults living both with and without human immunodeficiency virus (HIV), to see how safe it is, how well it triggers the body's immune response and how it affects the amount of virus in the body.

Read the detailed description

Currently, this study consists of one part (Part A) which will be a Phase I, randomized, placebo-controlled, double-blind, first-in-human (FIH), dose escalation with an initial proof-of-principle component. Depending on the safety and immunogenicity data generated in this study, the Phase II part of this study and/or some of the cohorts may not be initiated or may be terminated earlier by sponsor decision. In this study:

  • Three cohorts of people living without HIV (PLWOH) will be randomized in a 5:1 ratio to receive BNT168 or placebo. Participants in these cohorts will receive 3 injections. BNT168 will be evaluated for safety, reactogenicity, and vaccine-induced immunogenicity in this population.
  • Two cohorts of people living with HIV (PLWH), will be randomized in a 2:1 ratio to receive BNT168 or placebo. Participants in these cohorts will receive 4 injections. BNT168 will be evaluated in PLWH on combination antiretroviral therapy (cART) for safety, reactogenicity, and vaccine-induced immunogenicity in this population. An initial proof-of-principle assessment will be conducted in PLWH who undergo analytical treatment interruption (ATI) to evaluate viral kinetics after investigational medicinal product (IMP) administration. After the ATI period, cART will be restarted as per protocol.

For PLWOH, there will be an \~1-month screening period, \~2-month treatment period and an \~6-month follow-up period. The planned study duration per participant is \~9 months.

For PLWH, there will be an \~1-month screening period, \~6-month treatment period and an \~6-month follow-up period. The planned study duration per participant is maximum \~13 months.

02

Conditions studied

  • HIV -1 Infection

Browse trials for

Keywords

  • HIV (human immunodeficiency virus)
  • combination antiretroviral therapy (cART)
  • Acquired immunodeficiency syndrome (AIDS)
  • Ribonucleic acid (RNA)-based vaccine
03

In context

Acquired Immunodeficiency Syndrome Unverified

3,038 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.

This study's planned enrollment of 126 is above the median of 96 across 2,253 interventional studies indexed under Acquired Immunodeficiency Syndrome.

Browse Acquired Immunodeficiency Syndrome studies →

Lead sponsor

BioNTech SE is the lead sponsor of 76 studies on the registry; 25 are open to participants now.

Of its 33 completed or terminated interventional studies of FDA-regulated products, 26 (79%) have results posted.

Compared within Acquired Immunodeficiency Syndrome, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Are 18 to 50 years of age inclusive at the time of giving .
  • For PLWOH: Individuals who are -1 and HIV-2 negative at Visit 0. For PLWH: Individuals who are HIV-1 positive and HIV-2 negative at Visit 0.
  • Have not received an HIV vaccination or HIV broadly neutralizing antibody in another clinical study.
  • Are overall healthy as defined in the protocol.
  • Individuals who have screening hematology and/or blood chemistry laboratory values as defined in the protocol.
  • For PLWOH, starting at Visit 0 and continuously until the last planned visit in this study, individuals who:

    • Are assessed by the investigator as having a low likelihood of acquiring HIV and are committed to avoiding behaviors associated with a higher likelihood of acquiring HIV until the End of Study Visit.
    • Agree to discuss HIV disease risks.
    • Agree to HIV infection risk reduction counseling.
  • For PLWH, individuals who:

    • Have been on stable continuous cART for at least 12 months (defined as no interruptions longer than 14 continuous days) and with no changes in the components of the cART for at least 12 weeks prior to Visit 1.
    • Are not on a non-nucleoside reverse transcriptase inhibitor at screening.
    • Have never received lenacapavir and have not received other long-acting antiretroviral therapies in the last 2 years (i.e., intramuscular cabotegravir, cabotegravir-rilpivirine).
    • Are willing to undergo HIV transmission risk reduction counseling and to maintain low-risk behavior to protect their partners.
    • Have a of ≥500 cells/µL at Visit 0.
    • Per medical history, any available prior CD4+ T cell count must be ≥350 cells/µL.
    • Have plasma HIV-1 RNA levels of \<50 cps/mL for ≥6 months prior to study entry per investigator review of records and/or participant history (single measurements of \<200 cps/mL are allowed if preceded and followed by values of \<50 cps/mL).
    • Are willing to stop cART and undergo ATI at the timepoint defined in the protocol.
    • Are willing to re-initiate cART upon meeting cART restart criteria.
    • Site investigator anticipates that a fully active alternative cART regimen could be constructed and would be available in the event of virologic failure on the participant's current cART regimen.
  • Agree not to donate blood from the time of first IMP administration until 90 days after the last IMP administration for PLWOH and until the End of Study Visit for PLWH.

Key Exclusion Criteria:

  • Have had major surgery (e.g., major cardiopulmonary or abdominal operations) as per the investigator's judgment within 4 weeks before Visit 0, or will not have fully recovered from surgery, or have major surgery planned during the time the participants are expected to participate in the study.
  • Have an abnormal at Visit 0 as specified in the protocol.
  • Have any existing condition which may affect IMP injection and/or assessment of local reactions, e.g., tattoos, severe scars, etc.
  • Have any bleeding diathesis or condition associated with prolonged bleeding that, in the opinion of the investigator, could compromise their wellbeing if they participate in the study.
  • Have any current febrile illness (body temperature >38.0°C/>100.4°F) or other acute illness within 48 hours prior to IMP administration
  • Have any current or history of cardiovascular diseases, e.g., myocarditis, pericarditis, myocardial infarction, congestive heart failure, cardiomyopathy or arrhythmias, or any clinically significant cardiac disease per the investigator's judgment.
  • Have Grade ≥2 hypertension per Food and Drug Administration toxicity grading scale at screening.
  • Have a known or suspected impairment/alteration of immune function, disease, or immunodeficiency (except HIV for PLWH), including receipt of any immunostimulant, immunomodulator, medication, immunoglobulin, or blood/plasma product within 60 days prior to Visit 1 or planned administration during the study. Use of inhaled, intranasal, topical, or locally injected (e.g., intraarticular or intrabursal administration) is acceptable.
  • Have a history of within 5 years before screening. Exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or a malignancy which is considered in the investigator's judgment to have minimal risk of recurrence. Any malignancy that is an AIDS-defining illness per protocol is exclusionary regardless of perceived risk of recurrence.
  • Have received any within 28 days prior to Visit 0 or any other vaccines within 14 days prior to Visit 0 or who are planning to receive any vaccine within 28 days of each IMP dose. When possible, standard of care vaccinations should be planned with the study interventions in mind.
  • For PLWH: Have a history of opportunistic infections and/or AIDS-defining illnesses according to the US Centers for Disease Control and Prevention 2014 and the National Institutes of Health 2024.
  • For PLWOH: Have current untreated or incompletely treated active tuberculosis infection (by history or concerning symptoms). For PLWH: Have current untreated or incompletely treated active tuberculosis infection (by history or concerning symptoms or sputum molecular testing) or current latent tuberculosis infection (by blood interferon-gamma release assay [IGRA]). Not excluded: Participants who have a positive IGRA but were fully treated for latent or active tuberculosis infection, per history, review of available records, and per investigator discretion.
  • For PLWH: Have untreated or incompletely treated syphilis or genital, oropharyngeal or rectal gonorrhea or chlamydia infection.
  • For PLWH: Have a history of multi-class drug resistant HIV-1 infection defined as resistance to three or more classes of HIV drugs.
  • Have an estimated of \<45 mL/min/1.73 m2 using the 2021 chronic kidney disease epidemiology creatinine equation.
  • History of any serious adverse reactions (including anaphylaxis, respiratory distress, angioedema, or urticaria) to vaccines or to vaccine components such as lipids.
  • Have a history of progressive or severe neurologic disorder, seizure disorder, or Guillain-Barré syndrome.
  • Have a history of diabetes mellitus type 1 or type 2, a screening ≥6.5%, or are taking any medication for treatment of diabetes. (Not excluded: A history of isolated gestational diabetes.)

NOTE: Other protocol defined Inclusion/Exclusion criteria apply.

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
126 participants (estimated)

Study arms

  • Experimental
    A1 in PLWOH - BNT168 dose level 1

    Biological: BNT168

  • Experimental
    A2 in PLWOH - BNT168 dose level 2

    Biological: BNT168

  • Experimental
    A3 in PLWOH - BNT168 dose level 3

    Biological: BNT168

  • Experimental
    A4 in PLWH - BNT168 dose level 2

    This cohort will undergo ATI post vaccination

    Biological: BNT168

  • Experimental
    A5 in PLWH - BNT168 dose level 3

    This cohort will undergo ATI post vaccination

    Biological: BNT168

  • Placebo comparator
    PLWOH - Placebo

    Other: Placebo

  • Placebo comparator
    PLWH - Placebo

    PLWH participants receiving placebo will also undergo ATI post vaccination

    Other: Placebo

Interventions

  • BiologicalBNT168

    Intramuscular injection to be applied in the deltoid muscle, using the same non-dominant arm for all IMP injections

  • OtherPlacebo

    Isotonic sodium chloride (NaCl) solution (0.9%). Intramuscular injection to be applied in the deltoid muscle, using the same non-dominant arm for all IMP injections

06

What researchers measure

Primary outcomes

  1. Occurrence of at least one adverse event

    In PLWOH and PLWH. By cohort and pooled placebo.

    Time frame: From dosing through 28 days after each IMP dose

  2. Occurrence of at least one serious adverse event

    In PLWOH and PLWH. By cohort and pooled placebo.

    Time frame: From Dose 1 through the end of study (up to 12 months)

  3. Occurrence of at least one adverse event of special interest

    In PLWOH and PLWH. By cohort and pooled placebo.

    Time frame: From Dose 1 through the end of study (up to 12 months)

  4. Occurrence of at least one solicited local reaction (pain, erythema/redness, swelling) at the IMP injection site

    In PLWOH and PLWH. By cohort and pooled placebo. From dosing through 7 days after each IMP dose.

    Time frame: Up to 7 days after each IMP dose

  5. Occurrence of at least one solicited systemic event (vomiting, diarrhea, headache, fatigue/tiredness, myalgia/muscle pain, fever)

    In PLWOH and PLWH. By cohort and pooled placebo. From dosing through 7 days after each IMP dose.

    Time frame: Up to 7 days after each IMP dose

Secondary outcomes

  1. Occurrence of cytokine positive cluster of differentiation (CD) 4+ T cells

    In PLWOH and PLWH. By cohort and pooled placebo. For PLWOH, at 7 days post-Dose 2, and 7 days post-Dose 3. For PLWH, at 7 days post-Dose 2, 7 days post-Dose 3 and/or 7 days post-Dose 4. As assessed by multi-parameter intracellular cytokine staining (ICS) following stimulation with IMP-specific peptide pools.

    Time frame: Up to 7 days post-Dose 2, 3 and/or 4

  2. Occurrence of cytokine positive CD8+ T cells

    In PLWOH and PLWH. By cohort and pooled placebo. For PLWOH, at 7 days post-Dose 2 and 7 days post-Dose 3. For PLWH, at 7 days post-Dose 2, 7 days post-Dose 3 and/or 7 days post-Dose 4. As assessed by multi-parameter ICS following stimulation with IMP-specific peptide pools.

    Time frame: Up to 7 days post-Dose 2, 3 and/or 4

  3. Occurrence of proliferating CD8+ T cell responses (measured by carboxifluorescein diacetate succinimidyl ester)

    In PLWOH and PLWH. By cohort and pooled placebo. For PLWOH, at 28 days post-Dose 2 and 28 days post-Dose 3. For PLWH, at 28 days post-Dose 2, 28 days post-Dose 3 and 28 days post-Dose 4. As assessed by flow cytometry following stimulation with IMP-specific peptide pools.

    Time frame: At 28 days post-Dose 2, 3 and/or 4

  4. Magnitude of CD4+ T cell counts from ATI start through cART restart

    In PLWH. By cohort and pooled placebo.

    Time frame: Up to 168 days post ATI start

  5. Change in CD4+ T cell count from ATI start to cART restart and end of study

    In PLWH. By cohort and pooled placebo.

    Time frame: Up to 168 days post ATI start

  6. Occurrence of absolute CD4+ T cell count <350 cells/µL from ATI start through cART restart

    In PLWH. By cohort and pooled placebo.

    Time frame: Up to 168 days post ATI start

  7. Occurrence of at least one adverse event from the start of ATI to cART restart

    In PLWH. By cohort and pooled placebo.

    Time frame: Up to 168 days post ATI start

  8. Occurrence of at least one serious adverse event from the start of ATI to cART restart

    In PLWH. By cohort and pooled placebo.

    Time frame: Up to 168 days post ATI start

  9. Occurrence of any acquired immunodeficiency syndrome (AIDS)-defining illness or opportunistic infection from the start of ATI to cART restart

    In PLWH. By cohort and pooled placebo. AIDS-defining illnesses and opportunistic infections as listed in the protocol.

    Time frame: Up to 168 days post ATI start

  10. Time from ATI start to loss of virologic control (HIV-1 plasma viral load >200 copies [cps]/mL, confirmed by the next measurement)

    In PLWH. By cohort and pooled placebo.

    Time frame: Up to 168 days post ATI start

  11. Time from ATI start to meeting cART restart criteria

    In PLWH. By cohort and pooled placebo.

    Time frame: Up to 168 days post ATI start

07

Study locations

3 of 4 sites recruiting
  • The Crofoot Research Center
    Houston, Texas 77098, United States
    Recruiting
  • Perinatal HIV Research Unit (PHRU)
    Johannesburg, 1864, South Africa
    Not yet recruiting
  • Wits RHI - Shandukani Research
    Johannesburg, 2001, South Africa
    Recruiting
  • Clinical HIV Research Unit (CHRU)
    Johannesburg, 2092, South Africa
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Feb 2028, 18 months after the start.

Of 76 industry-sponsored phase 1 interventional studies under Acquired Immunodeficiency Syndrome, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 18. This study's planned 18 months is above that.

Counting every sponsor, half of 139 studies reached it within 14 months; a quarter within 4 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2026
First posted
Jul 13, 2026
StartActual
Aug 4, 2026
Primary completionEst.
Feb 2028
CompletionEst.
Feb 2028
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added — first site in South Africa
Show 3 added (3 South Africa)
  • Perinatal HIV Research Unit (PHRU) · Johannesburg, South Africa
  • Wits RHI - Shandukani Research · Johannesburg, South Africa
  • Clinical HIV Research Unit (CHRU) · Johannesburg, South Africa
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    3 sites added — first site in South Africa
    Show 3 added (3 South Africa)
    • Perinatal HIV Research Unit (PHRU) · Johannesburg, South Africa
    • Wits RHI - Shandukani Research · Johannesburg, South Africa
    • Clinical HIV Research Unit (CHRU) · Johannesburg, South Africa
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07698600
Lead sponsor
BioNTech SE
Responsible party
Sponsor
First posted
Jul 13, 2026
Start date
Aug 4, 2026
Primary completion
Feb 2028 (estimated)
Completion
Feb 2028 (estimated)
Last update
Oct 14, 2026

Study contacts

BioNTech clinical trials patient information
Contact
patients@biontech.de
+49 6131 9084 ext. 0
BioNTech Responsible Person
study director · BioNTech SE

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion